Spinal muscular atrophy, or SMA, is a rare, genetic neuromuscular disease characterized by the loss of motor neurons, atrophy of the voluntary muscles of the limbs and trunk, and progressive muscle weakness. An estimated 30,000 to 35,000 people in the United States and Europe are afflicted by SMA. Based on the age and severity of symptoms, SMA is classified into 4 types namely, types 1 through 4.
The company we are profiling today is developing a drug for nonambulatory patients with Types 2 and 3 spinal muscular atrophy - Scholar Rock Holding Corp. SRRK).
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.